Pharmacokinetics, distribution, metabolism and excretion of [3H]UCN-01 in rats and dogs after intravenous administration

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 2, 2001, Pages 106-112

  Yasoshima, K ^a   Kuwabara, T ^a   Fuse, E ^a   Kuramitu, T ^a   Kurata, N ^a   Nishiie, H ^a   Oishi, T ^a   Kobayashi, H ^a   Kobayashi, S ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

7 Hydroxystaurosporine (UCN 01); Excretion; Metabolism; Pharmacokinetics; Protein kinase inhibitor

Indexed keywords

7 HYDROXYSTAUROSPORINE; TRITIUM;

ANIMAL EXPERIMENT; ARTICLE; BILE DUCT; BLOOD; BRAIN LEVEL; CONTROLLED STUDY; DOG; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; FECES ANALYSIS; LIVER METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SIGNAL TRANSDUCTION; TESTIS; TISSUE DISTRIBUTION;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; BILE; DOGS; ENZYME INHIBITORS; FECES; MALE; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; STAUROSPORINE; TISSUE DISTRIBUTION;

EID: 0034918185     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000213     Document Type: Article

References (21)

1. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models
2. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C
3. Synergistic antitumor effect of UCN-01, a protein kinase (C) inhibitor, combined with various anti-cancer agents
4. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells
5. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor
6. 1-acid glycoprotein
7. 1-acid glycoprotein in humans
8. Noncompartmental analysis based on statistical moment theory
9. Modulation of apoptosis in rat thymocytes by analogs of staurosporine: Lack of direct association with inhibition of protein kinase C
10. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line
11. Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01
12. Blocking of glioma proliferation in in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor
13. Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models
14. Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms
15. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells
16. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function
17. 7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53
18. UCN-01, a selective inhibitor of protein kinase C from Streptomyces
19. Phase I study of UCN-01 by 3-hour infusion
20. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2
21. Determination of mean input time, mean residence time, and steady-state volume of distribution with multiple drug inputs